Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

227 results about "PHA binding" patented technology

Molecular lymphatic mapping of sentinel lymph nodes

The present invention describes a method for identification and labeling of sentinel lymph nodes (SLNs) and the presence or absence of lymph node metastases as an important diagnostic and prognostic factor in early stage cancers of all types. The method, know as Molecular Lymphatic Mapping, uses traditional dye / radioactive tracer based techniques in conjunction with a nucleic acid marker to identify and label the SLN, not only for current diagnostic methods, but for archival purposes. In addition, MLM can be used to deliver a therapeutic gene or genes to the SLN to activate tumor immunity to tumor cells, and / or to inhibit tumor metastases. The methods may be combined with therapeutic intervention including chemotherapy and radiotherapy.
Owner:JOHN WAYNE CANCER INST

Cancer therapy via a combination of epigenetic modulation and immune modulation

ActiveUS20160193239A1Improve immunityAnti-neoplastic effect of the immune modulating agent in the subject is enhancedOrganic active ingredientsMicrobiological testing/measurementAntiendomysial antibodiesImmune modulator
Cancer therapies that combine epigenetic modulating agent(s) with immune modulating agent(s), which were remarkably identified to provide an improved treatment regimen over single agent therapy, are disclosed. In particular embodiments, the invention provides for improved treatment of NSCLC in patients via administration of exemplary immune modulating agents anti-PD-1 antibody or anti-PD-L1 antibody, which were observed to show enhanced activity in combination with the exemplary epigenetic modulating agent 5-deoxyazacytidine. Further, expression markers of responsive neoplastic cells are also disclosed.
Owner:THE JOHN HOPKINS UNIV SCHOOL OF MEDICINE

Anti-human PD-1 humanized monoclonal antibody and application thereof

The invention relates to the field of biological medicine and particularly relates to an anti-human PD-1 humanized monoclonal antibody and application thereof. By virtue of sieving, the anti-human PD-1 humanized monoclonal antibody with favorable specificity and relatively high compatibility and stability is obtained, can be specifically combined with human PD-1, but is not combined with other members of the CD28 family, is capable of blocking combination of PD-L1 and PD-1 and partially restoring functions of T cells, and has an obvious inhibiting effect on tumor growth.
Owner:REYOUNG SUZHOU BIOLOGY SCI & TECH CO LTD

Monoclone antibody for anti HLA-G and hybrid tumour cell secreting same, cancer dignosis method, diagnosis reagent box and its application

A monoclonal antibody HGY for HLA-G, which can generate the antigen-antibody reaction on 7 HLA-G isomers, a hybridoma cell strain able to secrete it, a method with high sensitivity for diagnosing cancer with said antibody, and an immunohistochemical reagent kit prepared from said antibody and its application are disclosed.
Owner:四川首创生物制药有限公司

Adjuvant immune therapy in the treatment of solid tumors through modulation of signaling pathways following engagement of humoral and cell mediated responses

The invention combines a novel combination with two especially important aspects: first, the invention proposes to simultaneously stimulate response in white blood cells and a patient's tumor cells with a mitogen-challenging compound, preferably a lectin, in the preferred mode the selected lectin being phytohemagglutin ("PHA"), and second, to generate heat shock protein. A method of treatment is set out. The method of manufacturing proposed utilizes a system calculated to better insure sterility and streamline production of the cytokine modulator. A method of testing in conjunction with the therapy is also claimed utilizing clinical assessment of disease activity, patient performance status, and quality of life questionnaire. Should efficacy of a treatment fall off, particularly because of mutation or adaption, the composition and method may be re- applied. The invention is not limited to humans, but is also applicable to mammals. The composition is usable as a stand-alone composition, but preferably is used in conjunction with standard therapy such as radiation, chemotherapy or surgery, particularly surgical therapy, and in conjunction with the administration of cystine, as later defined, to enhance immune system competency.
Owner:KINDNESS GEORGE +2

CD137 antibody and application thereof

The invention relates to an antibody or an antigen-binding fragment thereof that binds to a CD137 protein with a KD value of 1*10<-9> M or less. The antibody or the antigen-binding fragment thereof has strong specific recognition and binding ability to the CD137 protein, and can activate a NF-[kappa]B signaling pathway, promote the proliferation of PBMC cells and / or induce immune cells to secretecytokines. The invention also provides an application of the antibody or the antigen-binding fragment thereof in preparation of drugs for treatment or prevention of cancer or autoimmune diseases.
Owner:SHANGHAI ORIGINCELL MEDICAL TECHNOLOGY CO LTD

Magnetic particle chemiluminescence immunoassay kit and assay method for human thyroglobulin antibodies (TGAb)

The invention relates to a magnetic particle chemiluminescence immunoassay method for human thyroglobulin antibodies (TGAb) and belongs to the technical field of immunoassay. TG antigens marked by fluorescein isothiocyanate (FITC) and human IgG antibodies marked by alkaline phosphatase are combined to form an antigen-antibody-second enzyme-labeled antibody sandwich immune complex with a sandwich-like structure. Then, magnetic particles connected with FITC antibodies are added, the antigen-antibody complex is connected to the magnetic particles through specific combination of the FITC antibodies and the FITC and directly deposited in an external magnetic field, and the complex formed by immune reaction can be separated from the other non-combined substances without centrifuging. A kit combines chemiluminescence with the magnetic particles to provide a reaction system close to a homogeneous phase. Compared with the prior art, the kit has the advantages of higher sensitivity, wide linear range, quickness and the like; the cost of a product is greatly reduced; and the kit has a broad application prospect on the aspects of clinical examination and the like.
Owner:JIANGSU ZECEN BIOTECH CO LTD

Therapy of Prostate Cancer With Ctla-4 Antibodies and Hormonal Therapy

The invention relates to methods for treating prostate cancer comprising administration of an anti-CTLA4 antibody, or an antigen-binding portion thereof, particularly a human antibody to human CTLA4, e.g., antibody 3.1.1, 4.1.1, 4.8.1, 4.10.2, 4.13.1, 4.14.3, 6.1.1, ticilimumab (also known as 11.2.1), 11.6.1, 11.7.1, 12.3.1.1, 12.9.1.1, and ipilimumab (also known as MDX-010 and 10D1), in combination with hormonal therapy. Hormonal therapy agents include, inter alia, an anti-androgen (e.g., megestrol, cyproterone, flutamide, nilutamide, and bicalutamide), a GnRH antagonist (e.g., abarelix and histrelin), and a LH-RH agonist (e.g., leuprolide, goserelin, and buserelin). The invention relates to neoadjuvant therapy, adjuvant therapy, therapy for rising PSA, first-line therapy, second-line therapy, and third-line therapy of prostate cancer, whether localized or metastasized.
Owner:PFIZER PFIZER PRODS

Kit for quantitatively testing free triiodothyronine and preparation method thereof

ActiveCN101949942AIncrease the effective coating amountReduce the impactBiological testingAntigenMagnetic bead
The invention discloses a kit for quantitatively testing free triiodothyronine, which comprises 3,3'-L-Diiodothyronine-gelatin enveloped magnetic bead suspension, a free triiodothyronine series calibrator, a horse radish peroxidase labeled free triiodothyronine antibody, chemiluminescent substrate A solution, chemiluminescent substrate B solution, and PBS buffer solution. The invention also discloses a method for preparing the kit. The kit has the advantages that: the chemiluminescence technology is combined with the immunomagnetic bead technology, the immunomagnetic beads are taken as a reaction carrier, the effective envelop amount of antigen is increased, raw materials are saved and the detection sensitivity and detection speed are obviously improved. A method for enveloping antigen analogs by the labeled antibody is adopted, so the analogs can be specifically combined with the antibody of hormone, but the combination capacity with thyroxine-binding protein is greatly reduced, and the influence of the binding protein on a measurement system is reduced to a large extent.
Owner:AUTOBIO DIAGNOSTICS CO LTD

Canine single-chain antibody, and construction method and application thereof

The invention relates to the technical field of biology, and particularly discloses a canine single-chain antibody, and a construction method and application thereof. By designing the canine antibody variable region degenerate primers, the canine heavy chain variable region VH and light chain variable region VL genes are successfully amplified. On such basis, a bacteriophage display technique is utilized to successfully construct the canine single-chain antibody scFv library. The scFv single-chain antibody library has diversity and enough storage capacity. A Dot-ELISA method is utilized to screen 3 single chain antibodies capable of being combined with the canine DEA 1.1 blood group antigen from the scFv single-chain antibody library by using the canine DEA 1.1 blood group antigen, wherein Clone 16 has stronger combination characteristic. A pET-32a-Clone16 recombinant protein is constructed according to the Clone 16 gene to perform prokaryotic expression, and the purified antibody has combination activity. The canine single-chain antibody lays solid foundation for preparing canine DEA 1.1 blood grouping reagents.
Owner:SOUTH CHINA AGRI UNIV

Construction and application of chimeric antigen receptor-T (CAR-T) cells capable of targeting mesothelin and carrying PD-L1 blocking agent

The invention relates to the field of tumor immunology, in particular to construction and application of chimeric antigen receptor-T (CAR-T) cells capable of targeting mesothelin and carrying a PD-L1blocking agent. The CAR-T cells are constructed by transfecting a CAR capable of targeting the mesothelin and carrying the PD-L1 blocking agent, wherein the CAR capable of targeting the mesothelin andcarrying the PD-L1 blocking agent is formed by a leader peptide of a CD8 antigen, an anti-mesothelin single-chain antibody, a hinge region, a transmembrane region, an intracellular signal domain andan anti-PD-L1 antibody secretion region which are sequentially connected with one another. The mesothelin SS1P scFv of the CAR-T cells provided by the invention can specifically bind to tumor cells expressing mesothelin glycoprotein and promote the secretion of anti-tumor-related cytokines, thereby achieving a killing effect on the tumor cells; furthermore, the CAR-T cells provided by invention can also secrete a PD-L1 antibody, specifically bind to PD-L1 produced by tumor cell expression, and block the inhibitory effect of a PD-L1 / PD-1 signal on T cell activity, thus facilitating the long-term effective inhibition of the CAR-T on tumor cell growth.
Owner:SUZHOU MAXIMUM BIO TECH CO LTD

Method of preparation for pharmaceutical grade plasmid DNA

This invention provides a process for the continuous alkaline lysis of a bacterial suspension in order to harvest pDNA. It further provides for optional additional purification steps, including lysate filtration, anion exchange chromatography, triplex affinity chromatography, and hydrophobic interaction chromatography. These optional purification steps can be combined with the continuous lysis in order to produce a highly purified pDNA product substantially free of gDNA, RNA, protein, endotoxin, and other contaminants.
Owner:AVENTIS PHARMA SA (US)

Combination therapy combining car + t cells with appropriately timed immunodulatory antibodies

In some embodiments, the present disclosure pertains to a method of enhancing chimeric antigen receptor expressing T cell function. In some embodiments, the method comprises activating the chimeric antigen receptor expressing T cells. In some embodiments, the method further comprises determining the differential expression of at least one molecule on the chimeric antigen receptor T cells. In some embodiments, the method comprises targeting the at least one molecule. In some embodiments, the present disclosure pertains to a method of treating a tumor in a subject in need thereof. In some embodiments, the method comprises administering to the subject an infusion of chimeric antigen receptor expressing T cells. In some embodiments, the method further comprises determining the differential expression of at least one molecule on the chimeric antigen receptor T cells. In some embodiments, the method comprises targeting the at least one molecule, wherein the molecule is differentially expressed upon activation of the chimeric antigen receptor expressing T cells.
Owner:UNIV HOUSTON SYST +1

Lysine acetylation site prediction method based on modular dense convolutional network

The invention discloses a lysine acetylation site prediction method based on a modular dense convolutional network, and the method comprises the steps: introducing the structural characteristics of aprotein, and combining the structural characteristics with the original sequence of the protein and the physicochemical attributes of amino acids to construct a site feature space; adopting a modulardense convolutional network to capture characteristic information of different hierarchies, and reducing information loss and information crosstalk in the characteristic learning process; and introducing a compression-excitation layer to evaluate the importance of different characteristics, so that the abstraction capability of the network is improved, and the potential lysine acetylation sites are identified. The method can effectively solve the problem that an existing method only considers protein sequence level information and is low in characteristic learning efficiency, potential lysineacetylation sites are more accurately predicted, the verification cost of the lysine acetylation sites is reduced, and the research efficiency of lysine acetylation modification is improved.
Owner:TAIYUAN UNIV OF TECH

Anti-Her2/PD-1 bispecific antibody and preparation method thereof

The invention discloses an anti-Her2 / PD-1 bispecific antibody and a preparation method thereof, and belongs to the field of biotechnology. The anti-Her2 / PD-1 bispecific antibody can bind to Her2 and bind to PD-1, and can effectively enhance immune response by blocking a Her2 and / or PD-1 signaling pathway, so that the anti-Her2 / PD-1 bispecific antibody is possible to have a good effect of enhancingthe anti-tumor immune response.
Owner:苏州塞恩塔生物技术有限公司

Method for detecting plasma protein binding rate of meropenem or imipenem by combining liquid chromatography-mass spectrometry technology with ultrafiltration technology

According to a method for detecting the plasma protein binding rate of meropenem or imipenem by combining a liquid chromatography-mass spectrometry technology with an ultrafiltration technology, the liquid chromatography-tandem mass spectrometry detection technology is combined with the ultrafiltration technology, and the total concentration of meropenem or imipenem in plasma and the free concentration of drugs in ultrafiltrate are respectively detected. And an MOPs stabilizer is added during sample treatment, so that the problem of poor drug stability is solved, and the determination result is more accurate. The method can be used for rapidly detecting the protein binding rate of the drug at high throughput, and is particularly suitable for unstable drug molecules.
Owner:PEKING UNIV THIRD HOSPITAL +1

Main cis-acting element of shrimp white spot syndrome virus (WSSV) iel promoter and transcription factor combined with same and application

The invention discloses a main cis-acting element of a shrimp white spot syndrome virus (WSSV) iel promoter and a transcription factor combined with the same and application. In the invention, by starting from transcriptional regulation of WSSV iel and carrying out structural and functional analysis on the promoter of the WSSV iel through deletion and mutation, a 12-bp DNA is found to be the maincis-acting element of the WSSV iel and is a crucial factor for the high expression of the iel. In the invention, a DNA affinity chromatography method is used for purifying a protein combined with a DNA segment from a nucleus protein Sf9, the protein is identified to be PHB2 (Poly-Beta-Hydroxybutyrate 2) through biological mass spectrometry, and the interaction between the protein and the DNA segment is proved to be specific by an electrophoretic mobility shift assay. Experiment results prove that PHB2 serves as a transcription factor and is specifically combined with a 12-bp DNA sequence of the iel promoter to start WSSV immediate early gene transcription so as to further regulate the replication of the WSSV, and can be used as an effective action target of medicaments for screening medicaments for resisting the shrimp WSSV.
Owner:HARBIN VETERINARY RES INST CHINESE ACADEMY OF AGRI SCI

Feces phage DNA extracting method, kit for extracting feces phage DNA and application of kit

PendingCN108410858AReduce extraction timeGood concentration and purityDNA preparationUltrafiltrationDna concentration
The invention belongs to the technical field of biology and discloses a feces phage DNA extracting method. According to the method, an ultrafiltration concentration method and a silica gel adsorptioncolumn method are combined; namely, an ultrafiltration concentrator is utilized to concentrate and purify phage at first, and then the silica gel adsorption column method is utilized to extract the phage DNA. The invention further discloses a kit for utilizing the feces phage DNA extracting method to extract the feces phage DNA and application of the kit. The method disclosed by the invention hasthe advantages that by improving the prior art, a 100-kDa ultrafiltration concentrator and a silica gel adsorption column are combined, and the feces phage DNA with a concentration about 53.47ng / mu Lcan be obtained within 5h. The feces phage DNA extracting method disclosed by the invention shortens extracting time, and the extracted DNA has better concentration and purity and can meet later qPRCand metagenome sequencing requirements.
Owner:SICHUAN UNIV

Application of ginseng PgWRKY4X transcription factor in regulating and controlling content of ginsenoside compounds in ginseng

The invention discloses an application of a ginseng PgWRKY4X transcription factor in regulating and controlling the content of ginsenoside compounds in ginseng. The amino acid sequence of the ginsengPgWRKY4X transcription factor is as shown in SEQ ID No. 1. Experiments prove that the ginseng PgWRKY4X transcription factor can be combined with a promoter of a ginseng PgSE gene, so the expression ofa key enzyme PgSE on a ginsenoside synthesis pathway is improved, and the content of ginsenoside compounds in ginseng is further improved. The ginseng PgWRKY4X transcription factor, an encoding geneof the ginseng PgWRKY4X transcription factor and an overexpression recombinant vector containing the encoding gene can be used for regulating and increasing the content of ginsenoside compounds in ginseng.
Owner:TIANJIN UNIV

Methods and systems for identifying ligand-protein binding sites

The invention provides a novel integrated structure and system-based approach for drug target prediction that enables the large-scale discovery of new targets for existing drugs Novel computer-readable storage media and computer systems are also provided. Methods and systems of the invention use novel sequence order-independent structure alignment, hierarchical clustering, and probabilistic sequence similarity techniques to construct a probabilistic pocket ensemble (PPE) that captures even promiscuous structural features of different binding sites for a drug on known targets. The drug's PPE is combined with an approximation of the drug delivery profile to facilitate large-scale prediction of novel drug-protein interactions with several applications to biological research and drug development.
Owner:KING ABDULLAH UNIV OF SCI & TECH

Polypeptide combined with Japanese encephalitis virus envelope protein and application of polypeptide

The invention mainly relates to polypeptide combined with Japanese encephalitis virus envelope protein and an application of the polypeptide. The sequence of the polypeptide is HRHHV, and is linear binding polypeptide, a polypeptide sequence serves as a core, the polypeptide sequence can be prolonged and modified, and modification materials comprise but are not limited to nanometer materials, fluorescent materials, enzymes, biotin and specific protein. Based on the phage peptide library screening technology, several rounds of screening are carried out through expressed and purified Japanese encephalitis virus envelope protein, and finally a polypeptide clone strain capable of being specifically combined with Japanese encephalitis virus envelope protein can be obtained. The clone strain is selected for sequence determination, and the core sequence of the polypeptide is HRHHV. The polypeptide is artificially synthesized for an ELISA binding experiment, and a result proves that the synthesized polypeptide can be combined with Japanese encephalitis virus envelope protein well. Compared with the process of artificially expressing protein and then carrying out immunization to obtain a protein antibody, the polypeptide is simple and convenient, and operation is easier. As the polypeptide is marked, and qualitative and quantitative detection can be fast carried out on Japanese encephalitis virus envelope protein.
Owner:ZHENGZHOU UNIV

Monoclonal antibody recongnizing epitope for HCV (hepatitis C virus) NS3 helicase ATP (adenosine triphosphate) binding site

InactiveCN102766195ATo achieve the purpose of treating HCVGood specificity recognition abilityImmunoglobulins against virusesAntiviralsEpitopeBinding site
The invention discloses a monoclonal antibody recongnizing epitope for HCV (hepatitis C virus) NS3 helicase ATP (adenosine triphosphate) binding site The epitope has the following amino acid sequence: PTGSGKSTK (SEQ ID NO: 1). The invention also discloses a monoclonal antibody capable of recongnizing the epitope and an application of the epitope and the monoclonal antibody. The monoclonal antibody recongnizing epitope for HCV NS3 helicase ATP binding site is a newly discovered NS3 protein epitope which lies in the ATP binding site of the first region of NS3C terminal helicase. The monoclonal antibody of the present invention can specifically identify the above-mentioned ATP binding site, making the activity of the helicase diminished or disappeared, thus affecting the combination of replication antibody of HCV and this site, and is expected to achieve the purpose of treating HCV.
Owner:SOUTHERN MEDICAL UNIVERSITY

Reversibly assembled and disassembled Strep-tag polypeptide-labeled biomolecule derivatization matrix and application thereof

InactiveCN104437411AExcellent biological targetingAchieve reversible captureOther chemical processesSolid sorbent liquid separationBio moleculesCompetitive binding
The invention discloses a reversibly assembled and disassembled Strep-tag polypeptide-labeled biomolecule derivatization matrix and an application thereof. Polypeptide can be linked on the surfaces of different matrixes on the basis of the characteristic that Strep-tag polypeptide can be bound to a matrix loaded with Strep-Tactin protein. Chemical derivatization is carried out on biological targeting molecules so as to form a biomolecule-Strep-tag conjugate; by virtue of specific recognition effects of the Strep-tag and the Strep-Tactin, the biomolecule-Strep-tag conjugate is immobilized on the surface of the matrix. After biotin is added, the linkage between the biomolecule and the matrix is destroyed due to the competitive binding between the biotin and the Strep-Tactin, so that reversible trapping and releasing on a to-be-detected object are achieved. The matrix is simple and rapid in preparing and using processes, good in repeatability, and is widely applicable to such fields of tumor marker detection, cell trapping and releasing, and the like.
Owner:WUHAN UNIV

Method applicable for fish blood cell fast classification and counting and application thereof

The invention discloses a method applicable for blood cell high-flux fast classification analysis of common fishes such as crucian and carps. By aiming at the problem of white blood cell classification and counting interference by removing-incapable nucleated red blood cells in two aspects of the quantity and the form, an automatic measurement and analysis strategy of combining the fluorochrome with the multi-channel images is utilized; the interference red blood cell sampling points are separated from the white blood cells according to the differences of particles in the cells, cell nucleus forms, positions and the like; different white blood cell class group range of lymphocyte, monocyte, particle cells and the like undertaking important immunologic functions is divided; the automatic analysis is completed. The difficulty that the nucleated red blood cells cannot be effectively removed troubles the automatic analysis of hemogram of various kinds of animals for a long time. The fluorochrome is combined with the imaging analysis; a high-flux and high-sensitivity measuring module of a multidimensional panoramic analyzer is used for accurately recognizing the red blood cell class groups; the interference is eliminated; the important technical support is provided for the focused analysis of the white blood cell class groups; wide application prospects are realized.
Owner:TIANJIN NORMAL UNIVERSITY

Immunofluorecence technique based method for evaluating activities of cryptosporidium parvum and giardia

The invention provides an immunofluorecence technique based method for evaluating activities of cryptosporidium parvum and giardia. The method has the following beneficial effects: the accurate, quick, simple, convenient and low-cost high throughput immunofluorecence assay technique is established and is used for evaluating the activities of cryptosporidium parvum and giardia in the ultraviolet (UV) disinfectant fluid; evaluation of the activities of cryptosporidium parvum and giardia in the UV irradiated water is realized by mainly carrying out competitive immunobinding on anti-pyrimidine-dimer (TDs) monoclonal antibodies and the TDs, taking fluorescein isothiocyanate as a marker and immunoglobulin (IgG) as a fluorescent substrate and binding 4',6-diamidino-2-phenylindole, dihydrochloride (DAPI); compared with the fluorescent staining method for evaluating the effect of UV on inactivating cryptosporidium parvum and giardia, the method provided by the invention has such excellent characteristics as strong specificity, high sensitivity and low professional operation requirements; and the cryptosporidium parvum and giardia activity evaluation method system is perfected by binding the method provided by the invention with the fluorescent staining method and other methods, and the method provided by the invention can be widely applied to the fields such as water quality monitoring, disease control and epidemic prevention and the like.
Owner:SHENZHEN POLYTECHNIC

Three-dimensional DNA nano-structure, electrochemical biosensor as well as preparation methods and application thereof

The invention relates to a three-dimensional DNA nano-structure, an electrochemical biosensor as well as preparation methods and application thereof. The three-dimensional DNA nano-structure is a hexahedron structure, and the hexahedron structure can be structurally transformed to cause electrochemical signal transformation by being combined with different target molecules. Four vertexes of the bottom surface of the three-dimensional DNA nano-structure unit are immobilized on the surface of a gold electrode through self-assembly action. According to the invention, the DNA nano-structure is assembled on the surface of the electrode to constitute the novel electrochemical biosensor, the DNA with the hexahedron structure has the characteristics of high-specificity target molecule recognition property and high stability, so that the analysis performance of the electrochemical biosensor is improved. The electrochemical biosensor provided by the invention can realize detection of different to-be-detected objects such as thrombin, lysozyme and the like by replacing a DNA chain and is wide in application range.
Owner:NORTHWEST UNIV

Thyroglobulin antibody detection kit and use method thereof

The invention discloses the technical field related to biological immune in-vitro diagnosis of medical instruments, and particularly relates to a thyroglobulin antibody detection kit and a use methodthereof. The kit comprises a calibration product, a quality control product, an anti-reagent, a magnetic particle reagent, a luminous substrate and a cleaning solution which are independently packaged, wherein the anti-reagents comprise a fluorescein isothiocyanate labeled thyroglobulin coating antigen and an alkaline phosphatase labeled anti-thyroglobulin labeled antibody; the magnetic particle reagent is prepared by coupling magnetic particles and a goat anti-fluorescein isothiocyanate antibody; a chemiluminescence technology is combined with immunomagnetic particles, so that the detection sensitivity and precision are greatly improved, the detection range is expanded, and the reaction time is short; a plurality of samples can be simultaneously determined on a full-automatic chemiluminiscence instrument, high-throughput quick determination of the thyroglobulin antibody is realized, the performance is reliable, the sensitivity is high, the linear range is wide, and the kit can be matched with semi-automatic and full-automatic instruments for use.
Owner:JIANGSU ZECEN BIOTECH CO LTD

Enriching method for transcription factor target gene through co-immunoprecititation of protein bead

The invention provides an enriching method for transcription factor target genes through co-immunoprecititation of protein beads. The method comprises the following steps: expressing transcription factor protein containing antigen labels, and subjecting the transcription factor protein containing antigen labels and monoclonal antibodies directed at the antigen labels to an immunoreaction so as toform antigen-antibody compounds; carrying out co-immunoprecititation on protein beads and the antigen-antibody compounds to form antigen-antibody-protein bead compounds which have absorbed transcription factor proteins; binding the antigen-antibody-protein bead compounds to DNA digested segments of genomes so as to remove DNA segments which can not bind to the transcription factors of the compounds, which means candidate target gene segments which can bind to the transcription factors are enriched; further constructing an insertion library of the enriched segments, and carrying out sequencingto obtain target genes of the transcription factors. According to the invention, the target genes capable of directly binding to transcription factor proteins can be obtained effectively from genomesthrough a simplified method thanks to the introduction of the beads and improvement to experimental steps.
Owner:BIOLOGICAL TECH INST OF FUJIAN ACADEMY OF AGRI SCI

Method for obtaining anti-idiotype antibodies

ActiveUS20060078943A1Efficient and economical to useSenses disorderAntipyreticAutoimmune conditionAutoimmune disease
A method for identifying molecules which mimic an idiotype of an autoimmune disease-associated auto-antibody (autoantibodies). The method comprises the following steps: (a) purifying autoantibodies from sera of one or more patients afflicted with the autoimmune disease; (b) binding the autoantibodies to a solid phase to form an affinity matrix; (c) contacting pooled plasma or B cells comprising immunoglobulins with the affinity matrix followed by removal of unbound plasma components; (d) eluting bound immunoglobulins, being anti-Idiotypic antibodies (anti-Id) to autoantibodies, from the matrix; (e) providing a molecular library comprising a plurality of molecule members; and (e) contacting the anti-Id with the molecular library and isolating those bound molecules which are bound by the anti-Id, the bound molecules being molecules which mimic an idiotype of autoantibodies. Also disclosed are such molecules.
Owner:OMRIX BIOPHARM
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products